Cargando…
The Tankyrase Inhibitor OM-153 Demonstrates Antitumor Efficacy and a Therapeutic Window in Mouse Models
The catalytic enzymes tankyrase 1 and 2 (TNKS1/2) alter protein turnover by poly-ADP-ribosylating target proteins, which earmark them for degradation by the ubiquitin–proteasomal system. Prominent targets of the catalytic activity of TNKS1/2 include AXIN proteins, resulting in TNKS1/2 being attracti...
Autores principales: | Brinch, Shoshy A., Amundsen-Isaksen, Enya, Espada, Sandra, Hammarström, Clara, Aizenshtadt, Aleksandra, Olsen, Petter A., Holmen, Lone, Høyem, Merete, Scholz, Hanne, Grødeland, Gunnveig, Sowa, Sven T., Galera-Prat, Albert, Lehtiö, Lari, Meerts, Ilonka A.T.M., Leenders, Ruben G.G., Wegert, Anita, Krauss, Stefan, Waaler, Jo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981206/ https://www.ncbi.nlm.nih.gov/pubmed/36873622 http://dx.doi.org/10.1158/2767-9764.CRC-22-0027 |
Ejemplares similares
-
Development of
a 1,2,4-Triazole-Based Lead Tankyrase
Inhibitor: Part II
por: Leenders, Ruben G. G., et al.
Publicado: (2021) -
Preclinical Lead
Optimization of a 1,2,4-Triazole
Based Tankyrase Inhibitor
por: Waaler, Jo, et al.
Publicado: (2020) -
Identification of response signatures for tankyrase inhibitor treatment in tumor cell lines
por: Mygland, Line, et al.
Publicado: (2021) -
Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models
por: Waaler, Jo, et al.
Publicado: (2020) -
An Evolutionary Perspective on the Origin, Conservation and Binding Partner Acquisition of Tankyrases
por: Sowa, Sven T., et al.
Publicado: (2022)